A Human Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) product, developed by Wuhan Hamilton Biotechnology Co., Ltd., recently passed inspection by the China National Institute for Food and Drug Control. As a result, the UC-MSCs are a qualified product for application in clinical trials.

Dongecheng Wu, MD, Ph.D., manager and chief scientist of Wuhan Hamilton Biotechnology Co., Ltd. and his team will begin a study entitled “Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis.” Dr. Wu is also the chairman of the Scientific Advisory Board of BHI Therapeutic Sciences. 

“Stem cells have been shown to migrate to sites of injury and inflammation where they are believed to support the survival of damaged cell and inhibit the immune responses,” said Dr. Wu. “Stem cell application in clinical trials shows promising results in therapy of neurological, musculoskeletal, cardiovascular and metabolic diseases,” he added.

The study will be conducted at Union Hospital, Tongji Medical College Huazhing University of Science and Technology. This study is the first clinical research project registered in Hubei Province with the China Medical Biotechnology Association.

Brian Mehling, MD, founder and chief medical officer of the BHI Therapeutic Sciences and long-time scientific partner with Dr. Wu, said “Stem cell research is the most exciting option in the field of regenerative medicine being tested for efficacy in treating a variety of health issues where the body’s own response to traditional treatment isn’t sufficient to restore health and optimum function.”

“Together with Dr. Wu, we are focused on bringing advanced stem cell therapies within reach of a wider audience, “said Dr. Mehling. We support continued research into regenerative medicine,” he added. 

Dr. Mehling is a practicing American orthopedic trauma surgeon, researcher, and member of the prestigious International Society for Stem Cell Research. He conducts research in regenerative medicine and stem cell science.

Dr. Wu is a Professor at Wuhan University School of Basic Medical Science and a Chu Tian Scholar.BHI Therapeutic Sciences supports investigational research and education in stem cell and regenerative medicine using cord blood cells.   Its stem cell products evaluated in clinical studies are collected in accordance with Good Tissue Practice to ensure safety. The studies have been conducted following approval by an Investigational Research Board and in accordance with Good Clinical Practice. Its cellular products are investigational and have not been shown to be safe or effective for any disease or condition. Multiple studies of umbilical cord blood derived stem cell therapies and adipose-derived stem cell therapies are currently under investigation in clinical trials for a wide-range of medical conditions and show promising results. BHI Therapeutic Sciences has registered stem cell research studies on ClinicalTrials.gov. Its cellular products are investigational, are not approved by the U.S. FDA, and no representation of FDA approval is made. For more information, please visit www.bhisciences.com.